BTTX - Better Therapeutics names Myovant Sciences' finance chief as new CEO

Better Therapeutics (NASDAQ:BTTX) stated Tuesday that Frank Karbe has been appointed as company's new President and CEO, effective July 5, 2022.  Current CEO and company co-founder, Kevin Appelbaum, will continue to serve in that role until then.  Frank joins in from Myovant Sciences (MYOV), where he had been serving as President and CFO leading its growth from a private start-up to a publicly listed commercial-stage company and raising $2B in capital. Earlier, Frank has served as EVP and CFO of Exelixis (EXEL) and as an investment banker for Goldman Sachs & Co. Earlier (May 24): Better Therapeutics up 69% in 3x higher than normal volume

For further details see:

Better Therapeutics names Myovant Sciences' finance chief as new CEO